Treatment and Prophylaxis of Gout Flare in the Clinic: An Office-Based Approach to Gout Management

References

• . Schlesinger N. Diagnosis of gout: Clinical, laboratory, and radiologic findings. Am J Manag Care. 2005; 11( 15 suppl):S443–S450; quiz S465–S468
   PubMed Web of Science ®Google Scholar
• . Eggebeen AT. Gout: An update. Am Fam Physician. 2007; 76(6): 801–808
   PubMedGoogle Scholar
• . Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006; 8( suppl 1):S3
   PubMed Web of Science ®Google Scholar
• . Chu SC, Yang SF, Tzang BS, Hsieh YS, Lue KH, Lu KH. Cathepsin B and cystatin C play an inflammatory role in gouty arthritis of the knee. Clin Chim Acta. 2010; 411(21–22):1788–1792
   PubMedGoogle Scholar
• . Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout: New insights into pathogenesis and treatment. Bull NYU Hosp Jt Dis. 2007; 65(3):215–221
   PubMedGoogle Scholar
• . Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999; 59(7):1799–1806
   PubMed Web of Science ®Google Scholar
• . Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: Epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010; 26(12):2813–2821
   PubMed Web of Science ®Google Scholar
• . Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care. 2005; 11( 15 suppl):S459–S464; quiz S465–S468
   PubMed Web of Science ®Google Scholar
• . Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: The National Health and Nutrition Examination Survey (NHANES). Arthritis Rheum. 2010; 62( suppl 10):S901. Abstract 2154
   Google Scholar
• . Bieber JD, Terkeltaub RA. Gout: On the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004; 50(8):2400–2414
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R. Update on gout: New therapeutic strategies and options. Nat Rev Rheumatol. 2010; 6(1):30–38
   PubMed Web of Science ®Google Scholar
• . Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008; 35(3):498–501
   PubMed Web of Science ®Google Scholar
• . Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006; 8( suppl 1):S2
   PubMed Web of Science ®Google Scholar
• . Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum. 2010; 62(4):1069–1076
   PubMed Web of Science ®Google Scholar
• . Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011; 50(5):973–981
   PubMed Web of Science ®Google Scholar
• . Lee SJ, Hirsch JD, Terkeltaub R, . Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009; 48(5):582–586
   PubMedGoogle Scholar
• . Sarkin AJ, Levack AE, Shieh MM, . Predictors of doctor-rated and patient-rated gout severity: Gout impact scales improve assessment. J Eval Clin Pract. 2010; 16(6):1244–1247
   PubMedGoogle Scholar
• . Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977; 20(3):895–900
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Pascual E, ; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65(10):1301–1311
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Bardin T, ; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65(10):1312–1324
   PubMed Web of Science ®Google Scholar
• . Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004; 31(12):2429–2432
   PubMed Web of Science ®Google Scholar
• . Chui CH, Lee J Y. Diagnostic dilemmas in unusual presentations of gout. Aust Fam Physician. 2007; 36(11):931–934
   PubMed Web of Science ®Google Scholar
• . Mandell BF, Edwards NL, Sundy JS, Simkin PA, Pile JC. Preventing and treating acute gout attacks across the clinical spectrum: A roundtable discussion. Cleve Clin J Med. 2010; 77( suppl 2):S2–S25
   PubMedGoogle Scholar
• . Peláez-Ballestas I, Hernández Cuevas C, Burgos-Vargas R, . Diagnosis of chronic gout: Evaluating the American College of Rheumatology proposal, European League Against Rheumatism recommendations, and clinical judgment. J Rheumatol. 2010; 37(8):1743–1748
   PubMedGoogle Scholar
• . Simmonds HA, Duley JA, Fairbanks LD, McBride MB. When to investigate for purine and pyrimidine disorders. Introduction and review of clinical and laboratory indications. J Inherit Metab Dis. 1997; 20(2):214–226
   PubMed Web of Science ®Google Scholar
• . Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002; 47(6):610–613
   PubMedGoogle Scholar
• . Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: Recent advances. Curr Rheumatol Rep. 2002; 4(3):270–274
   PubMedGoogle Scholar
• . Nyhan WL, O'Neill JP, Jinnah HA, Harris JC. Lesch-Nyhan Syndrome. In: Pagon RA, Bird TD, Dolan CR, eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 2000
   Google Scholar
• . Jinnah HA. Lesch-Nyhan disease: From mechanism to model and back again. Dis Model Mech. 2009; 2(3–4):116–121
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; (8 suppl 1):S4
   PubMed Web of Science ®Google Scholar
• . Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004; 31(8):1582–1587
   PubMed Web of Science ®Google Scholar
• . Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: A pilot study. Ann Rheum Dis. 2000; 59(7):539–543
   PubMed Web of Science ®Google Scholar
• . Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: An administrative claims analysis. J Clin Rheumatol. 2009; 15(1):3–7
   PubMed Web of Science ®Google Scholar
• . Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr. 2008; 87(5):1480–1487
   PubMed Web of Science ®Google Scholar
• . Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med. 2005; 165(7):742–748
   PubMed Web of Science ®Google Scholar
• . Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: Prospective cohort study. BMJ. 2008; 336(7639): 309–312
   PubMedGoogle Scholar
• . Choi HK, Zhu Y, Mount DB. Genetics of gout. Curr Opin Rheumatol. 2010; 22(2):144–151
   PubMedGoogle Scholar
• . Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005; 1(2):80–86
   PubMedGoogle Scholar
• . Suppiah R, Dissanayake A, Dalbeth N. High prevalence of gout in patients with Type 2 diabetes: Male sex, renal impairment, and diuretic use are major risk factors. N Z Med J. 2008; 121(1283):43–50
   PubMedGoogle Scholar
• . Cannella AC, Mikuls TR. Understanding treatments for gout. Am J Manag Care. 2005; 11( 15 suppl):S451–S458; quiz S465–S468
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Schumacher HR Jr. Gout: Can management be improved? Curr Opin Rheumatol. 2001; 13(3):240–244
   PubMed Web of Science ®Google Scholar
• . Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349(17): 1647–1655
   PubMed Web of Science ®Google Scholar
• . Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002; 14(3):281–286
   PubMed Web of Science ®Google Scholar
• . Anker SD, Doehner W, Rauchhaus M, . Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003; 107(15):1991–1997
   PubMed Web of Science ®Google Scholar
• . Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987; 82(3):421–426
   PubMedGoogle Scholar
• . Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med. 1999; 131(1):7–13
   PubMed Web of Science ®Google Scholar
• . Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005; 45(1):18–20
   PubMedGoogle Scholar
• . Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke. 2003; 34(8):1951–1956
   PubMed Web of Science ®Google Scholar
• . Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007; 57(1):109–115
   PubMed Web of Science ®Google Scholar
• . Yamamoto T, Moriwaki Y, Takahashi S, . A simple method of selecting gout patients for treatment with uricosuric agents, using spot urine and blood samples. J Rheumatol. 2002; 29(9):1937–1941
   PubMedGoogle Scholar
• . Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: Comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009; 15(1):22–24
   PubMed Web of Science ®Google Scholar
• . Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010; 170(13):1120–1126
   PubMed Web of Science ®Google Scholar
• . Janssens HJ, Janssen M, van de Lisdonk EH, Fransen J, van Riel PL, van Weel C. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis. 2010; 69(6):1255–1256
   PubMedGoogle Scholar
• . Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst A W. Serum urate levels and gout flares: Analysis from managed care data. J Clin Rheumatol. 2006; 12(2):61–65
   PubMed Web of Science ®Google Scholar
• . Stamp LK, Zhu X, Dalbeth N, Jordan S, Edwards NL, Taylor W. Serum urate as a soluble biomarker in chronic gout–evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers. Semin Arthritis Rheum. 2011; 40(6):483–500
   PubMedGoogle Scholar
• . Sivera F, Aragon R, Pascual E. First metatarsophalangeal joint aspiration using a 29-gauge needle. Ann Rheum Dis. 2008; 67(2):273–275
   PubMedGoogle Scholar
• . Quest Diagnostics I. Uric acid, synovial fluid #4403. 2011. http://www.questdiagnostics.com/hcp/testmenu/jsp/showTestMenu.jsp?fn=4403.html&labCode=CNL. Accessed January 27, 2011
   Google Scholar
• . Colcrys [package insert]. Philadelphia, PA; Mutual Pharma; 2010
   Google Scholar
• . Uloric [package insert]. Deerfield, IL; Takeda Pharmaceuticals America; 2009
   Google Scholar
• . Doghramji PP. Managing your patient with gout: A review of treatment options. Postgrad Med. 2011; 123(3):56–71
   PubMed Web of Science ®Google Scholar
• . Krystexxa [package insert]. East Brunswick, NJ; Savient Pharmaceuticals, Inc; 2010
   Google Scholar
• . Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet. 2008; 371(9627):1854–1860
   PubMed Web of Science ®Google Scholar
• . Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial. Ann Emerg Med. 2007; 49(5): 670–677
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Chen LX. The practical management of gout. Cleve Clin J Med. 2008; 75( suppl 5):S22–S25
   PubMedGoogle Scholar
• . Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009; 38(6):411–419
   PubMed Web of Science ®Google Scholar
• . Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237–241
   PubMed Web of Science ®Google Scholar
• . Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis M W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3 A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011; 63(8):2226–2237
   PubMed Web of Science ®Google Scholar
• . Keenan RT, Pillinger MH. Hyperuricemia, gout, and cardiovascular disease—an important “muddle”. Bull NYU Hosp Jt Dis. 2009; 67(3):285–290
   PubMedGoogle Scholar
• . Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis M W. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010; 62(4):1060–1068
   PubMed Web of Science ®Google Scholar
• . Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987; 17(3):301–304
   PubMedGoogle Scholar
• . Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic review. Rheumatology (Oxford). 2006; 45(11):1422–1431
   PubMedGoogle Scholar
• . Underwood M. Diagnosis and management of gout. BMJ. 2006; 332(7553):1315–1319
   PubMedGoogle Scholar
• . Naprosyn [package insert]. Nutley, NJ; Roche Laboratories Inc; 2008
   Google Scholar
• . Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991; 12(7):423–429
   PubMed Web of Science ®Google Scholar
• . Anaprox [package insert]. Corona, CA; Watson Labs; 2007
   Google Scholar
• . Laporte JR, Carné X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991; 337(8733):85–89
   PubMedGoogle Scholar
• . Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: Newer versus older agents. Drug Saf. 2004; 27(6):411–420
   PubMed Web of Science ®Google Scholar
• . Rubin BR, Burton R, Navarra S, . Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum. 2004; 50(2):598–606
   PubMed Web of Science ®Google Scholar
• . Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med. 2010; 21(3):157–163
   PubMed Web of Science ®Google Scholar
• . Ng G, Chau EM, Shi Y. Recent developments in immune activation by uric acid crystals. Arch Immunol Ther Exp (Warsz). 2010; 58(4):273–277
   PubMed Web of Science ®Google Scholar
• . Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging. 1998; 13(3):229–243
   PubMedGoogle Scholar
• . Schumacher HR Jr, Boice JA, Daikh DI, . Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002; 324(7352):1488–1492
   PubMed Web of Science ®Google Scholar
• . Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553):1302–1308
   PubMed Web of Science ®Google Scholar
• . Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002; 54(3):320–326
   PubMed Web of Science ®Google Scholar
• . Rostom A, Muir K, Dubé C, . Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007; 5(7):818–828
   PubMed Web of Science ®Google Scholar
• . Bavry AA, Khaliq A, Gong Y, Handberg EM, Cooper-Dehoff RM, Pepine CJ. Harmful Effects of Nonsteroidal Anti-inflammatory Drugs among Patients with Hypertension and Coronary Artery Disease. Am J Med. 2011; 124(7):614–620
   PubMed Web of Science ®Google Scholar
• . Salvo F, Fourrier-Reglat A, Bazin F, ; Investigators of Safety of Non-Steroidal Anti-Inflammatory Drugs: SOS Project. Cardiovascular and Gastrointestinal Safety of NSAIDs: A Systematic Review of Meta-Analyses of Randomized Clinical Trials. Clin Pharmacol Ther. 2011; 89(6):855–866
   PubMed Web of Science ®Google Scholar
• . Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, . Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study. Circulation. 2011; 123(20):2226–2235
   PubMed Web of Science ®Google Scholar
• . Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation. 2007; 115(12):1634–1642
   PubMed Web of Science ®Google Scholar
• . Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract. 2003; 20(4):413–416
   PubMed Web of Science ®Google Scholar
• . Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54(8):2688–2696
   PubMed Web of Science ®Google Scholar
• . Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008; 168(10):1104–1110
   PubMed Web of Science ®Google Scholar
• . Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993; 20(1):111–113
   PubMedGoogle Scholar
• . Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994; 21(7):1325–1327
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Baker DG, Schumacher HR Jr. Serum urate during bouts of acute gouty arthritis. J Rheumatol. 1997; 24(11):2265–2266
   PubMedGoogle Scholar
• . Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010; 22(2):165–172
   PubMed Web of Science ®Google Scholar
• . Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: The Multiple Risk Factor Intervention Trial. Rheumatology (Oxford). 2010; 49(12):2391–2399
   PubMedGoogle Scholar
• . Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6):585–591
   PubMedGoogle Scholar
• . Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974; 17(5):609–614
   PubMedGoogle Scholar
• . Becker MA, Schumacher HR Jr, Wortmann RL, . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450–2461
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR Jr, Wortmann RL, . Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52(3):916–923
   PubMedGoogle Scholar
• . Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin Ther. 2010; 32(14):2386–2397
   PubMed Web of Science ®Google Scholar
• . Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010; 49(1):105–111
   PubMedGoogle Scholar
• . Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout—what are the treatment options? Expert Opin Pharmacother. 2009; 10(8):1319–1328
   PubMed Web of Science ®Google Scholar
• . Abraham NS, Hlatky MA, Antman EM, ; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010; 122(24):2619–2633
   PubMed Web of Science ®Google Scholar
• . Jordan KM, Arden NK, Doherty M, ; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12):1145–1155
   PubMed Web of Science ®Google Scholar
• . Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: Administrative claims analysis. Curr Med Res Opin. 2009; 25(7):1711–1719
   PubMed Web of Science ®Google Scholar
• . Harrold LR, Andrade SE, Briesacher B, . The dynamics of chronic gout treatment: Medication gaps and return to therapy. Am J Med. 2010; 123(1):54–59
   PubMed Web of Science ®Google Scholar
• . Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol. 2004; 31(8):1575–1581
   PubMed Web of Science ®Google Scholar